Bicher A - Search Results

1

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Bicher A, et al. Cancer. 1993 Jan 15;71(2 Suppl):594-600. doi: 10.1002/cncr.2820710216. Cancer. 1993. PMID: 7678382 Clinical Trial.

2

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, et al. Kohn EC, et al. Among authors: bicher a. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24. doi: 10.1093/jnci/86.1.18. J Natl Cancer Inst. 1994. PMID: 7505830 Clinical Trial.

3

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.

Link CJ Jr, Bicher A, Kohn EC, Christian MC, Davis PA, Adamo DO, Reed E, Sarosy GA. Link CJ Jr, et al. Among authors: bicher a. Blood. 1994 Mar 1;83(5):1188-92. Blood. 1994. PMID: 7509652 Free article. Clinical Trial.

4

The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.

Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO, Jacob J, Christian M, Reed E. Bicher A, et al. Anticancer Drugs. 1993 Apr;4(2):141-8. doi: 10.1097/00001813-199304000-00003. Anticancer Drugs. 1993. PMID: 7683933

5

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Reed E, et al. Among authors: bicher a. Cancer Res. 1993 Aug 15;53(16):3694-9. Cancer Res. 1993. PMID: 8339278 Clinical Trial.

6

Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988.

Reed E, Zerbe CS, Brawley OW, Bicher A, Steinberg SM. Reed E, et al. Among authors: bicher a. Am J Clin Oncol. 2000 Apr;23(2):107-16. doi: 10.1097/00000421-200004000-00002. Am J Clin Oncol. 2000. PMID: 10776968

7

Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.

Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E. Yu JJ, et al. Among authors: bicher a. Cancer Lett. 2000 Apr 14;151(2):127-32. doi: 10.1016/s0304-3835(99)00390-0. Cancer Lett. 2000. PMID: 10738106

8

Loss of heterozygosity in human ovarian cancer on chromosome 19q.

Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Bicher A, et al. Gynecol Oncol. 1997 Jul;66(1):36-40. doi: 10.1006/gyno.1997.4709. Gynecol Oncol. 1997. PMID: 9234918

9

Infusion site soft-tissue injury after paclitaxel administration.

Bicher A, Levenback C, Burke TW, Morris M, Warner D, DeJesus Y, Gershenson DM. Bicher A, et al. Cancer. 1995 Jul 1;76(1):116-20. doi: 10.1002/1097-0142(19950701)76:1<116::aid-cncr2820760118>3.0.co;2-p. Cancer. 1995. PMID: 8630862

10

Urinary symptoms in women receiving carboplatin/paclitaxel for treatment of gynecologic cancers.

Strauchon CJ, Dengler KL, Gruber DD, Katebi Kashi P, Aungst MJ, Trikhacheva A, Bicher A, Von Pechmann W. Strauchon CJ, et al. Among authors: bicher a. Int J Gynecol Cancer. 2020 Sep;30(9):1418-1423. doi: 10.1136/ijgc-2020-001529. Epub 2020 Jul 12. Int J Gynecol Cancer. 2020. PMID: 32655011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters